Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation
Blood Research
;
: 55-57, 2013.
Artículo
en Inglés
| WPRIM
| ID: wpr-132573
ABSTRACT
Tacrolimus is a widely used immunosuppressive agent for the prophylaxis of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation (HSCT). Since tacrolimus is primarily metabolized by the liver, hepatic dysfunction may affect its metabolism. Hepatic veno-occlusive disease (VOD) is an early complication of HSCT that results in hepatic dysfunction, suggesting that VOD may affect tacrolimus metabolism. We report a case of hepatic VOD accompanied by a sustained high blood trough level of tacrolimus despite its discontinuation. The findings of this case suggest that the elimination of tacrolimus can be markedly delayed in patients with hepatic VOD, and that the clinician should carefully modulate the drug dosage for these patients.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Enfermedad Veno-Oclusiva Hepática
/
Células Madre Hematopoyéticas
/
Tacrolimus
/
Trasplante de Células Madre Hematopoyéticas
/
Enfermedad Injerto contra Huésped
/
Hígado
Límite:
Humanos
Idioma:
Inglés
Revista:
Blood Research
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS